Get to know our clinical trials
A Trial of Autologous T Cells with a CD19-Specific Chimeric Antigen Receptor (CABA-201) in Patients with Active Systemic Lupus Erythematosus
THE PURPOSE OF THIS STUDY IS TO DETERMINE WHAT DOSE OF THE STUDY DRUG, CALLED CABA-201, CAN BE SAFELY ADMINISTERED TO PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), INCLUDING THOSE WITH LUPUS NEPHRITIS (LN).
Technical Summary
- AN OPEN-LABEL PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AUTOLOGOUS T CELLS EXPRESSING A CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CABA-201) IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS
- Code EudraCT: 2023-507613-10-00
- Protocol number: CAB-201-001
- Promoter: Cabaletta Bio, Inc
- Molecule/Drug: Autologous CD19-specific chimeric antigen receptor T cells (CABA-201)
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.